Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
grade A 14.52 -0.75% -0.11
ARWR closed down 0.75 percent on Friday, January 18, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical ARWR trend table...

Date Alert Name Type % Chg
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Wide Bands Range Expansion -0.75%
Jan 17 Overbought Stochastic Strength -0.75%
Jan 16 Wide Bands Range Expansion 0.07%
Jan 16 Overbought Stochastic Strength 0.07%
Jan 15 Narrow Range Bar Range Contraction -0.95%
Jan 15 NR7 Range Contraction -0.95%
Jan 15 Inside Day Range Contraction -0.95%

Older signals for ARWR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Is ARWR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.39
52 Week Low 4.77
Average Volume 1,714,678
200-Day Moving Average 13.2845
50-Day Moving Average 13.6206
20-Day Moving Average 13.362
10-Day Moving Average 14.578
Average True Range 0.9074
ADX 14.05
+DI 23.1437
-DI 19.6613
Chandelier Exit (Long, 3 ATRs ) 12.5578
Chandelier Exit (Short, 3 ATRs ) 13.1322
Upper Bollinger Band 16.0388
Lower Bollinger Band 10.6852
Percent B (%b) 0.72
BandWidth 40.065858
MACD Line 0.364
MACD Signal Line 0.2129
MACD Histogram 0.1511
Fundamentals Value
Market Cap 1.09 Billion
Num Shares 74.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -22.69
Price-to-Sales 11.15
Price-to-Book 2.81
PEG Ratio -1.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.81
Resistance 3 (R3) 15.81 15.39 15.60
Resistance 2 (R2) 15.39 15.06 15.39 15.52
Resistance 1 (R1) 14.95 14.86 14.74 14.95 15.45
Pivot Point 14.53 14.53 14.42 14.53 14.53
Support 1 (S1) 14.09 14.20 13.88 14.09 13.59
Support 2 (S2) 13.67 14.00 13.67 13.52
Support 3 (S3) 13.23 13.67 13.45
Support 4 (S4) 13.23